Stephanie Traxinger, DO
Family Medicine · Bismarck, NDNPI 1366608465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $922 and has fallen 90.8% since, to $85 in 2024. Among family medicine clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$437
- Astellas Pharma US Inc$402
- Amgen$376
- Lilly USA, LLC$283
- Pfizer$203
- Sanofi-aventis U.S. LLC$202
- plus $701 from 12 others
What the payments were for
- Food & beverage$2,46395%
- Education$1405%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $437 |
| Astellas Pharma US Inc | 20 | $402 |
| Amgen | 25 | $376 |
| Lilly USA, LLC | 27 | $283 |
| Pfizer | 12 | $203 |
| Sanofi-aventis U.S. LLC | 13 | $202 |
| AbbVie(2 entities) | 10 | $165 |
| Johnson & Johnson | 7 | $100 |
| Abbott | 6 | $83 |
| Novartis | 4 | $75 |
| AstraZeneca | 5 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Merck | 3 | $38 |
| Boehringer Ingelheim | 1 | $18 |
| GSK | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$2,603 in reported general payments places this provider in the 90th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $142,842 |
| JardianceEmpagliflozin | 98 | $87,507 |
| RybelsusSemaglutide | 45 | $58,267 |
| JanuviaSitagliptin Phosphate | 62 | $41,059 |
| XareltoRivaroxaban | 49 | $38,467 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $31,727 |
| MyrbetriqMirabegron | 38 | $21,047 |
| TrulicityDulaglutide | 21 | $20,378 |
| OzempicSemaglutide | 20 | $20,308 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $12,002 |
| SynthroidLevothyroxine Sodium | 132 | $10,809 |
| FarxigaDapagliflozin Propanediol | 19 | $10,415 |
| Levothyroxine Sodium | 516 | $6,894 |
| Rosuvastatin Calcium | 503 | $5,879 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $5,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $203 | $142,842187 claims |
| Boehringer IngelheimJardiance | $18 | $87,50798 claims |
| Novo NordiskRybelsus, Ozempic | $437 | $78,57565 claims |
| MerckJanuvia | $38 | $41,05962 claims |
| Johnson & JohnsonXarelto | $100 | $38,46749 claims |
| Astellas Pharma US IncMyrbetriq | $402 | $21,04738 claims |
| Lilly USA, LLCTrulicity | $283 | $20,37821 claims |
| AbbVieSynthroid | $165 | $10,809132 claims |
| AstraZenecaFarxiga | $68 | $10,41519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Bismarck
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
- Stuart SmithBismarck$8K
- David PengillyBismarck$8K
- Biron BakerBismarck$8K
- Michelle TincherBismarck$7K
- Kevin LongieBismarck$6K
- Kelly LongieBismarck$5K
- Sherry SteinBismarck$5K
- David FieldBismarck$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.